Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin

This article was originally published in The Pink Sheet Daily

Executive Summary

Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.

You may also be interested in...

Lilly Not Ducking M&A, But Will Play To Strengths In Cancer And Diabetes

The Indiana-based big pharma will focus on product-level acquisitions in its core areas of strengths now that it has rounded out its animal health business with its $5.4 billion acquisition of Novartis Animal Health.

Vedolizumab, Empagliflozin And Vintafolide Receive Positive EU Opinions After CHMP Meeting

The three new medicines tackle ulcerative colitis and Crohn’s disease, diabetes and ovarian cancer, respectively, with final approval from the European Commission expected in around two months.

AstraZeneca’s Farxiga Label Includes, But Downplays, Bladder Cancer Risk

AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts